For a long time, people diagnosed with mesothelioma didn’t have many options. Surgery and chemotherapy were the standard treatments, and even then, the results were often limited. In the last several years, though, things have begun to shift.
Clinical trials are opening doors that didn’t exist before. These studies test new treatments that could improve survival and quality of life, giving patients access to tomorrow’s therapies while they’re still in development. Some focus on new forms of immunotherapy, while others look at targeted drugs or gene-based approaches designed to stop cancer where it starts.
These trials aren’t reckless experiments. They’re closely monitored, regulated, and often free to join. For many families, they’ve become rare and valuable in the world of mesothelioma: real hope grounded in science.
What Is a Clinical Trial?
Clinical trials are research studies testing new treatments, procedures, or combinations to see if they work better than the options doctors already have. Every medicine and therapy we use today, from chemotherapy to vaccines, was once studied in a clinical trial.
Each trial moves through four main phases, and each one answers different questions:
- Phase I focuses on safety. Doctors test a new drug or treatment in a small group to find the safest dose and learn how it affects the body.
- Phase II assesses whether it works by measuring tumor response and symptom improvement.
- Phase III measures the new treatment against the current standard of care to see which performs better.
- Phase IV continues monitoring long-term safety and effectiveness once the treatment is FDA-approved.
Patient safety is always the top priority. Trials are reviewed by ethics boards and overseen by medical teams who monitor participants closely. In fact, patients in trials often receive more frequent checkups and testing than they would during standard treatment.
Today, mesothelioma research is expanding into exciting new areas, including:
- Immunotherapy combinations that strengthen the immune system’s ability to fight cancer.
- Targeted therapies that block specific genetic changes driving tumor growth.
- Gene-based and personalized medicine is designed around each patient’s unique tumor profile.
Every one of these studies brings researchers closer to better, longer-lasting treatments and, for patients, offers access to options that might not exist anywhere else.
Why Clinical Trials Matter for Mesothelioma
Because mesothelioma is rare, doctors don’t have as much data to guide treatment decisions as they do for other cancers. That’s what makes clinical research so important. Every trial and every participant helps scientists learn faster and improve care for everyone who comes after.
Some of the most promising advances in mesothelioma treatment have come directly from clinical trials.
For example, studies testing the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) led to their FDA approval in 2020 for patients whose cancer can’t be removed by surgery. Those drugs now give thousands of people a real chance at longer survival and better quality of life.
Taking part in a trial doesn’t just benefit science. It can help the patient, too. Participants often gain access to new drugs or combinations years before they’re available to the public. Real people today are living longer because others said yes to trials just a few years ago. That progress only continues when patients and families keep choosing to participate.
Who Can Join a Clinical Trial?
Not everyone with mesothelioma will qualify for every trial, but many patients are eligible for at least one. Eligibility usually depends on a few main factors:
- The type and stage of mesothelioma — pleural (in the chest), peritoneal (in the abdomen), or pericardial (around the heart).
- Previous treatments, such as surgery, chemotherapy, or immunotherapy.
- Overall health and organ function, since certain drugs can put extra strain on the body.
You don’t have to wait until every other option is exhausted to consider a clinical trial. Many people join early in their treatment plan to access new therapies while they’re still strong enough to tolerate them.
Importantly, participating in a trial is always voluntary. You can leave at any time, for any reason. The goal is to give you more choices, not fewer and to make sure you stay in control of your care every step of the way.
Common Myths About Clinical Trials
Even though clinical trials are a cornerstone of progress in cancer care, many people hesitate to join because of misunderstandings. Clearing up these myths can make the idea feel less intimidating and more like what it really is: a chance to explore new options safely.
Myth #1: “I’ll be treated like a test subject.”
In reality, people who join clinical trials aren’t treated like test subjects at all. These studies follow strict safety and ethical guidelines, and review boards and medical teams oversee every trial. Participants get close, attentive care from doctors, nurses, and researchers who are there to keep them safe and supported throughout the process.
Myth #2: “I might get a placebo and no treatment.”
That’s a common fear, but it’s not how cancer trials work. In almost all cancer studies, participants receive an active treatment, either the new therapy being tested or the current best standard of care. You’ll always get some form of recognized, evidence-based treatment.
Myth #3: “It’s only for people with no other options.”
Many patients join trials early in their treatment journey. Doing so can give access to promising therapies while you’re still strong enough to tolerate them. Trials aren’t just a “last resort.” They’re often an opportunity to expand your treatment plan.
Myth #4: “It costs too much to join.”
Most clinical trials cover the costs of the experimental treatment and often help with travel or lodging. You may still be responsible for routine medical expenses, but your research team will explain all costs upfront so there are no surprises.
How to Find Clinical Trials
If you or someone you love is interested in a clinical trial, there are several trusted ways to find legitimate and current studies:
- Talk to your oncologist or nurse navigator. They can help you find trials that match your type and stage of mesothelioma.
- Search reliable databases. The National Cancer Institute (cancer.gov) and clinicaltrials.gov list ongoing studies and eligibility requirements.
- Contact major cancer centers. Hospitals like MD Anderson Cancer Center, Brigham and Women’s Hospital, and the University of Chicago Medicine often run their own mesothelioma trials.
- Reach out to advocacy organizations. Groups like the Mesothelioma Applied Research Foundation can connect patients and families with open trials and help with the application process.
Taking the first step can feel overwhelming, but you don’t have to do it alone. Doctors, nurse navigators, and advocacy groups are there to guide you through every part of the process, from understanding eligibility to arranging logistics.
The Role of Legal Compensation
Even though many clinical trials cover the cost of the experimental treatment, families may still incur expenses for travel, lodging, or missed work. That’s where legal compensation can make a real difference.
Because mesothelioma is nearly always linked to asbestos exposure, patients may be eligible to file claims against the companies responsible. Those funds can help cover the out-of-pocket costs that often come with pursuing advanced care, whether it’s getting to a specialty center, joining a trial, or paying for extended stays near a hospital.
Looking Ahead: The Future of Mesothelioma Research
Mesothelioma research is moving faster than ever. Scientists are exploring personalized vaccines that teach the immune system to recognize specific tumor mutations, as well as gene-based therapies that repair or replace damaged genetic material. CAR-T cell and TCR therapies, which re-engineer a patient’s own immune cells to attack cancer, are showing early promise.
Researchers are also studying biomarkers that can help predict who will respond best to each treatment, allowing for more precise, tailored care.
Every one of these advances builds on the courage of patients who chose to participate in trials before these treatments were mainstream. Each contribution moves the entire field forward.
Taking the Next Step
If you’re living with mesothelioma, consider asking your oncologist about clinical trials at your next appointment. Exploring these options doesn’t mean giving up standard treatments. It simply means opening the door to more possibilities.
Each study, each participant, brings us closer to turning mesothelioma from a devastating diagnosis into a disease that can be managed and one day, cured.
Author: David Foster
Over the last 15 years, David has worked with the Dandell team to build a group of professionals whose goal is to make clients feel like their voices matter and that they are part of a family.
Reviewed by: Devan El Dana, PharmD
Medical Disclaimer: MesoCare.org provides educational information and is not a medical provider. We are not doctors. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician with any questions regarding a medical condition. Treatments mentioned are options that may help and should be discussed with a specialist.
Legal Disclaimer: MesoCare.org is a resource center and advocacy group, not a law firm. We do not provide legal advice or guarantee specific financial outcomes. No attorney-client relationship is formed by using this site or contacting an advocate. Potential compensation or grant amounts are estimates and vary by individual case.
Sources
[1] Cancer clinical trials information. (n.d.). Cancer.gov. https://www.cancer.gov/research/participate/clinical-trials
[2] The basics. (2025, April 24). National Institutes of Health (NIH). https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics
[3] Suraya, R., Nagano, T., & Tachihara, M. (2025). Recent advances in mesothelioma treatment: immunotherapy, advanced cell therapy, and other innovative therapeutic modalities. Cancers, 17(4), 694. https://doi.org/10.3390/cancers17040694
[4] Immunotherapy for mesothelioma. (n.d.-b). American Cancer Society. https://www.cancer.org/cancer/types/malignant-mesothelioma/treating/immunotherapy.html
[5] Štrbac, D., & Dolžan, V. (2022). Novel and Future Treatment Options in Mesothelioma: A Systematic review. International Journal of Molecular Sciences, 23(4), 1975. https://doi.org/10.3390/ijms23041975